Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
Hosted on MSN3d
PBMs made more than $7B marking up specialty generics: FTCThe three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty ...
The Arkansas Pharmacists Association is calling for public and legislative support for stronger regulation of Pharmacy ...
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...
For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.
In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback